A conserved tryptophan at the membrane–water interface acts as a gatekeeper for Kir6.2/SUR1 channels and causes neonatal diabetes when mutated
Open Access
- 29 June 2011
- journal article
- research article
- Published by Wiley in The Journal of Physiology
- Vol. 589 (13) , 3071-3083
Abstract
Non‐technical summary Neonatal diabetes is a rare genetic form of diabetes that develops within the first 6 months of life. It is often caused by genetic defects (mutations) in a specialised membrane protein known as the KATP channel. This protein acts as a tiny pore in the membrane of the insulin‐secreting cells in the pancreas and its opening and closing is regulated by blood glucose levels. Low blood glucose holds the pore open and prevents insulin secretion whereas high blood sugar leads to channel closure and insulin secretion. We identified a novel mutation (Kir6.2‐W68R) that prevents channel closure and insulin secretion, and so results in neonatal diabetes. Detailed molecular studies showed that channel opening and closing is disrupted, suggesting Kir6.2‐W68 may act as a channel ‘gatekeeper’. Our results also indicated that the mutant channel could be shut by sulphonylurea drugs, which enabled the patient to transfer from insulin injections to tablet therapy.Keywords
This publication has 46 references indexed in Scilit:
- PIP2-Binding Site in Kir Channels: Definition by Multiscale Biomolecular SimulationsBiochemistry, 2009
- Identification of the PIP2‐binding site on Kir6.2 by molecular modelling and functional analysisThe EMBO Journal, 2007
- Studies of the ATPase activity of the ABC protein SUR1The FEBS Journal, 2007
- Mutations in ATP-Sensitive K+ Channel Genes Cause Transient Neonatal Diabetes and Permanent Diabetes in Childhood or AdulthoodDiabetes, 2007
- A Kir6.2 Mutation Causing Neonatal Diabetes Impairs Electrical Activity and Insulin Secretion From INS-1 β-CellsDiabetes, 2006
- Functional analysis of six Kir6.2 (KCNJ11) mutations causing neonatal diabetesPflügers Archiv - European Journal of Physiology, 2006
- Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 geneDiabetologia, 2006
- Switching from Insulin to Oral Sulfonylureas in Patients with Diabetes Due to Kir6.2 MutationsNew England Journal of Medicine, 2006
- A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetesHuman Molecular Genetics, 2006
- KATP channels as molecular sensors of cellular metabolismNature, 2006